Login to Your Account



Other News To Note


Wednesday, November 7, 2012

• Cleveland BioLabs Inc., of Buffalo, N.Y., published results in the Journal of Immunology showing efficacy of entolimod (CBLB502) against graft-vs.-tumor activity in allogeneic bone marrow transplantation in mouse models.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription